Voriconazole in the treatment of allergic bronchopulmonary aspergillosis in cystic fibrosis

Abstract

Allergic bronchopulmonary aspergillosis (ABPA) can cause a significant clinical deterioration in patients with cystic fibrosis. There is very little research in the current literature with regand to alternatives for treatment, apart from long courses of steroids. We conducted a retrospective review of all our patients with ABPA treated with the antifungal voriconazole and found there was a significant drop in IgE levels post treatment as well as a decrease in steroid dosing. The improvement in FEV1 was not statistically significant; however there was a very wide variation in pre-treatment levels. © Copyright 2004 - 2005. Irish Medical Journal.